PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

Company Overview

PROCEPT BioRobotics, Inc. is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures. The system is designed for use in an outpatient setting, offering physicians a controlled robotic platform to carry out targeted tissue resection without the need for thermal energy. This approach is intended to minimize complications such as urinary incontinence and sexual dysfunction often associated with conventional BPH treatments.

Headquartered in Redwood City, California, PROCEPT BioRobotics was founded in 2008 by Serdar Bozkurt, MD, who continues to serve as Chief Medical Officer. The AquaBeam Robotic System received U.S. Food and Drug Administration (FDA) clearance in 2016 and a CE mark for European markets, positioning the company to serve healthcare providers across North America and select international territories. PROCEPT has built a network of clinical partners and distributors to support physician training and system installation.

With a focus on advancing urological care through innovation, PROCEPT BioRobotics invests in ongoing research and development to expand its platform’s capabilities and explore new indications. The company maintains collaborations with leading academic institutions and surgical centers to refine procedural protocols and gather long-term clinical data, underscoring its commitment to evidence-based adoption of robotic waterjet ablation technology.

Key Stats

• Today's Range: $27.74 to $29.08
• 50-Day Range: $21.71 to $28.69
• 52-Week Range: $19.35 to $66.85
• Volume: 312,609 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $1.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.45
• Consensus Rating: Hold

PROCEPT BioRobotics Stock Analysis - MarketRank™

PROCEPT BioRobotics scored higher than 80% of companies evaluated by MarketBeat, and ranked 118th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

PROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 8 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

PROCEPT BioRobotics has a consensus price target of $41.45, representing about 44.7% upside from its current price of $28.66.

Amount of Analyst Coverage

PROCEPT BioRobotics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.53) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PROCEPT BioRobotics is -15.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PROCEPT BioRobotics is -15.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PROCEPT BioRobotics has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.77% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 4.15.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently increased by 2.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PROCEPT BioRobotics does not currently pay a dividend.

Dividend Growth

PROCEPT BioRobotics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 0.99

News Sentiment

PROCEPT BioRobotics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PROCEPT BioRobotics this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

22 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $9,909,625.00 in company stock, which represents 0.6075% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, PROCEPT BioRobotics insiders have bought 1,728.02% more of their company's stock than they have sold. Specifically, they have bought $10,483,091.00 in company stock and sold $573,466.00 in company stock.

Percentage Held by Insiders

6.60% of the stock of PROCEPT BioRobotics is held by insiders.

Percentage Held by Institutions

89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/29/2026
• Today: 5/21/2026
• 46th Annual William Blair Growth Stock Conference: 6/02/2026
• Truist Securities MedTech Conference 2026: 6/16/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PRCT
• CIK: 1588978
• Web: www.procept-biorobotics.com
• Phone: 650-232-7200
• Fax: N/A
• Employees: 430
• Year Founded: 2009

Price Target and Rating

• Average Price Target for PROCEPT BioRobotics: $41.45
• High Price Target: $70.00
• Low Price Target: $20.00
• Potential Upside/Downside: +44.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.57 million
• Net Margins: -31.82%
• Pretax Margin: -31.76%
• Return on Equity: -27.70%
• Return on Assets: -20.29%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 6.73
• Quick Ratio: 5.51

Sales & Book Value

• Annual Sales: $308.05 million
• Price / Sales: 5.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.11 per share
• Price / Book: 4.70

Miscellaneous

• Outstanding Shares: 56,920,000
• Free Float: 53,162,000
• Market Cap: $1.63 billion
• Optionable: Optionable
• Beta: 0.83